Recently, I wrote about biotech’s grand illusion, the five-act play that begins with obscurity, peaks with capital, and ends in quiet disappearance. Many companies have already played the final scene. Some are mid-collapse. Others still appear upright — runway intact, investor decks refreshed, and LinkedIn profiles unchanged.

But look closer, and you’ll see the same cracks forming.

These aren’t failed companies. Not yet. But they are structurally unsustainable. Despite massive capital raised, billion-dollar valuations, and years of operation, they sit on a trajectory where breakeven is a decade away, at best. If they survive at all.

They fit every characteristic I described in May:

• Complex science, poorly understood.
• Valuations untethered from clinical proof.
• Net income deep in the red, year after year.
• A burn rate that outpaces any plausible path to product.

This is the same five-act collapse, still in motion. And we need to talk about it before the curtain falls again.

Act I: The Idea Becomes Untouchable

It always begins with an idea, not necessarily a bad one, but one wrapped in layers of abstraction and technical mystique. The kind of idea that sounds revolutionary to those outside the core scientific circle, yet lacks true clarity or direct translatability.

Rather than emerging from clinical necessity or a deep understanding of biological complexity, these companies are often built around the belief that sophisticated platforms alone can reshape biomedicine. Their stories begin not with patients or problems, but with technologies: data-centric, algorithmic, generative. Impressive in design but frequently disconnected from the lived reality of disease. They generate outputs with remarkable efficiency, yet what’s missing is the grounding — the humility to interrogate biology before predicting it, the discipline to solve foundational problems before scaling ambition.

What results is a compelling performance: a promise of transformation, played out on a stage increasingly distant from the clinic.

Eventually, the idea is no longer discussed, it’s simply assumed. It enters the realm of biotech dogma, protected by its distance from validation. Internal teams may raise concerns, but the incentives rarely support dissent. To challenge the idea is to challenge the foundation of the company itself.

We’re not discussing potential anymore. We’re managing mythology. And in mythology, doubt is heresy.

Act II: The Capital Is Already Spent

Despite the absence of clinical proof, or often even preclinical robustness, the capital came pouring in. Series A, B, C… perhaps even an IPO. Each round justifying the last, each valuation leap signaling credibility, not sustainability.

But the truth is, the capital was never connected to execution. It was connected to narrative velocity. Investment wasn’t based on a rigorous evaluation of what had been built, but on the momentum of what had been promised.

What remains now is not a war chest. It’s a burn clock. The largest expense lines are often real estate, platform development, and internal expansion — not clinical trials, not patients, not outcomes. And now, many of these companies operate with a paradoxical tension: enormous cumulative funding, but almost no remaining room for error.

They raised to be big, not to be right. And now, there’s no room left to pivot without signaling collapse.

Act III: The Burn Is the Business Model

Years into development, some of these companies still haven’t reached the clinic, or have done so with marginal, non-pivotal studies. The science remains locked in a preclinical maze, with new targets added as old ones fail to validate, and programs shelved in favor of “re-focusing”.

What keeps going is not the pipeline, it’s the process. Internal R&D cycles loop endlessly. Outsourced CRO work fills the pipeline update slides. Product-market fit is replaced by investor-story fit.

Burn rates of $40–80 million per year are normalized. And with each year, the distance between scientific potential and financial reality widens. The team works hard, but in a structure that rewards activity over outcomes.

In a traditional business, this would be called unsustainable. In biotech, it’s still called innovation.

Act IV: The Illusion Is Sustained by Momentum

You can walk into one of these companies today and see polished labs, sleek websites, recent conference panels, even job openings. On the surface, they look like thriving ventures.

But inside, the tone is different. Resignations increase. Strategies shift monthly. Clinical trial timelines quietly slip by quarters, then years. Product messaging starts to feel more like tech PR than translational medicine.

Still, the illusion holds. Investors aren’t ready to mark down yet. Boards are reluctant to pull the plug. So the company continues, as long as the quarterly updates have enough jargon and the financial runway isn’t quite empty.

What sustains the company is not conviction in the science, it’s fear of admitting that the story has run its course.

Act V: The System Refuses to Learn

When these companies finally collapse, as many will, the failure will not be treated as instructive. It will be treated as circumstantial. “The model was too early”. “The market turned”. “The approach just needed more time”.

Founders will move on, often upward. Institutional investors will recycle their thesis with new wrappers. Journalists and analysts will quietly delist coverage without postmortem. Nothing is learned. Because no one is incentivized to learn.

The system is designed to erase failure and valorize repetition. The same actors return to the stage under new banners, with new platforms, for new indications, and the illusion begins again.

In biotech, experience is rarely tied to results. It’s tied to fundraising velocity, not patient impact.

The Collapse Is Already Underway

This article isn’t about the companies that are gone. It’s about the ones still standing, barely.

They are not exceptions. They are not unlucky. They are the logical product of a system that rewards abstraction, funds momentum, and avoids accountability.

The five acts are not theoretical. They are playing out right now, in plain sight.

And unless we start telling the truth about how this happens, we’ll all be back here soon. Same model. Same outcome. Same illusion.

Different company. Same collapse.